Compare Citius Pharmaceuticals Inc (CTXR) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tractor Supply Co — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Tractor Supply Co trades at $33.7 (market cap $17.44B). The key difference: Tractor Supply Co is far larger — about 1280.5× Citius Pharmaceuticals Inc's market cap, and Tractor Supply Co pays a 2.87% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Tractor Supply Co for 89 Days on average.
| CTXR | TSCO | |
|---|---|---|
Market Cap | $13.62M | $17.44B |
Volume | 132,438 | 10,598,723 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $56.37 |
52-Week Low | $0.48 | $29.14 |
Typical Hold Time | 17 Days | 89 Days |
Enterprise Value | $3.79M | $23.76B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Tractor Supply (TSCO) trades at $33.48, up 2.95% today, showing resilience after recent earnings misses. The stock maintains a bullish technical outlook with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates consistent revenue growth reaching $15.52B in 2025, with healthy profitability metrics including 36.46% gross margin and 39.51% ROE. Recent corporate developments include new distribution center openings and ongoing community investment initiatives.
The investment outlook remains cautiously optimistic with a $36.76 consensus price target representing 9.8% upside potential. Key opportunities include the company's 17-year dividend growth streak and strategic expansion, while risks center on consecutive earnings misses and institutional selling pressure. The balanced analyst coverage (48% buy, 50% hold) reflects uncertainty about near-term performance amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
